APLS logo

Apellis Pharmaceuticals (APLS) Company Overview

Profile

Full Name:

Apellis Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

November 9, 2017

Indexes:

Not included

Website:

http://www.apellis.com

Description:

Reata Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 2002. Based in the city of Plano, Texas, the company is involved in the development of new treatment methods based on the use of low molecular weight therapeutic agents with new mechanisms of action for the treatment of severe, life-threatening diseases. The main products of the company are bardoxolone methyl (a drug for the treatment of rare forms of chronic kidney disease (CKD)) and omaveloxolone (a drug for the treatment of rare neurological diseases). Both bardoxolone and omaveloxolone normalize mitochondrial function, restore redox balance, and eliminate inflammation. Since mitochondrial dysfunction, oxidative stress, and inflammation are features of many diseases, bardoxolone and omaveloxolone have a variety of potential clinical applications.

Key Details

Price

$24.10

Market Cap

$3.00 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$781.37 M(+97.02% YoY)

Annual EPS

-

PE Ratio

-

Annual ROE

-86.58%

Annual Debt To Equity

2.06

Beta

1.33

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 28, 2025

Recent annual earnings:

Feb 28, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Oct 16, 24 William Blair
Outperform
Oct 16, 24 Scotiabank
Sector Perform
Sep 24, 24 Wells Fargo
Equal-Weight
Sep 23, 24 Baird
Outperform
Sep 20, 24 Needham
Buy
Sep 20, 24 Mizuho
Neutral
Sep 13, 24 JP Morgan
Overweight
Aug 13, 24 JP Morgan
Overweight
Aug 9, 24 Wedbush
Neutral
Aug 9, 24 UBS
Buy

Screeners with APLS included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks with high beta
Stocks below SMA 200
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$24.10
APLS price is $24.10

Price All-time High

$93.86
APLS price is currently -74.33% below its historical high of $93.86

Price Analysts Target

$44.50
APLS price is currently -45.85% lower than the consensus analysts' forecast

Price Today Change

-3.61%
APLS price is down -3.61% today

Price YTD Change

-26.22%
APLS price is down -26.22% since January 1st

Price 3-Year Change

-45.46%
APLS price is down -45.46% over the past 3 years

Market cap

Market Cap

$3.00 B
APLS market capitalization is $3.00 billion

Market Cap 3-Year Change

-30.58%
APLS market capitalization is down -30.58% over the past 3 years

Market Cap All-time High

$10.93 B
APLS market capitalization is currently -72.58% below its historical high of $10.93 billion

Market Cap Sector Rank

85.28%
APLS market capitalization is higher than 85.28% of companies in Healthcare sector

Technical

Beta

1.33
APLS beta is 1.33

200-day SMA

$33.95
APLS price is currently -29.02% below its 200-day simple moving average

14-day RSI

28.40
APLS 14-day relative strength index is 28.40

30-day Relative Volume

0.87
APLS 30-day relative volume is 0.87

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$781.37 M
APLS annual revenue is $781.37 million

Annual Revenue Analysts Estimate

$868.28 M
APLS annual revenue is currently -10.01% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+97.02%
APLS annual revenue is up +97.02% year-on-year

Annual Revenue Sector Rank

78.36%
APLS annual revenue is higher than 78.36% of companies in Healthcare sector

Profit

Annual Gross Profit

$663.64 M
APLS annual gross profit is $663.64 million

Annual Gross Margin

84.93%
APLS annual gross profit margin is 84.93%

Annual Operating Profit

-$164.98 M
APLS annual operating income is -$164.98 million

Annual Operating Margin

-21.11%
APLS annual operating profit margin is -21.11%

Annual Net Income

-$197.88 M
APLS annual net profit is -$197.88 million

Annual Net Margin

-
APLS annual net profit margin value is unknown

EPS

Annual EPS

-
APLS annual earnings per share value is unknown

Annual EPS Analysts Estimate

-$1.24
APLS annual earnings per share is currently equal to the consensus analysts' forecast

Annual EPS 1-Year Change

-
APLS annual earnings per share 1-year change is unknown

Annual EPS Sector Rank

-
APLS annual earnings per share is unknown

ROA & ROE

Annual ROA

-22.36%
APLS annual return on assets is -22.36%

Annual ROE

-86.58%
APLS annual return on equity is -86.58%

EBIT & EBITDA

Annual EBIT

-$156.32 M
APLS annual earnings before interest & taxes is -$156.32 million

Annual EBITDA

-$152.58 M
APLS annual EBITDA is -$152.58 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
APLS price to earnings ratio value is unknown

PE Ratio Sector Rank

-
APLS price to earnings ratio is unknown

PB Ratio

PB Ratio

13.12
APLS price to book ratio is 13.12

PB Ratio Sector Rank

94.15%
APLS price to book ratio is higher than 94.15% of companies in Healthcare sector

PS Ratio

PS Ratio

3.84
APLS price to sales ratio is 3.84

PS Ratio Sector Rank

57.03%
APLS price to sales ratio is higher than 57.03% of companies in Healthcare sector

Enterprise value

Enterprise Value

$3.06 B
APLS enterprise value is $3.06 billion

Enterprise Value Sector Rank

84.93%
APLS enterprise value is higher than 84.93% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-19.78
APLS EV/EBITDA is -19.78

EV/EBITDA Sector Rank

6.43%
APLS EV/EBITDA is higher than 6.43% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.25
APLS annual current ratio is 4.25

Annual Quick Ratio

3.81
APLS annual quick ratio is 3.81

Leverage

Annual Debt To Equity

2.06
APLS annual debt to equity ratio is 2.06

Annual Interest Coverage Ratio

-3.87
APLS annual interest coverage ratio is -3.87

Risk & Stability

Piotroski F-Score

3
APLS piotroski f-score is 3

Altman Z-Score

-0.94
APLS altman z-score is -0.94

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$885.05 M
APLS annual total assets is $885.05 million

Annual Non Current Assets

$96.10 M
APLS annual long term assets is $96.10 million

Annual Current Assets

$788.95 M
APLS annual total current assets is $788.95 million

Annual Cash & Cash Equivalents

$411.29 M
APLS annual cash & cash equivalents is $411.29 million

Equity

Annual Book Value

$228.54 M
APLS annual book value is $228.54 million

Annual Working Capital

$603.45 M
APLS annual working capital is $603.45 million

Liabilities

Annual Total Liabilities

$656.51 M
APLS annual total liabilities is $656.51 million

Annual Total Long Term Liabilities

$471.00 M
APLS annual total long term liabilities is $471.00 million

Annual Current Liabilities

$185.51 M
APLS annual total current liabilities is $185.51 million

Annual Accounts Payable

$38.57 M
APLS annual accounts payable is $38.57 million

Debt

Annual Total Debt

$469.78 M
APLS annual total debt is $469.78 million

Annual Total Debt 1-Year Change

+323.5%
APLS annual total debt is up +323.5% year-on-year

Annual Long Term Debt

$463.03 M
APLS annual long term debt is $463.03 million

Annual Short Term Debt

-
APLS annual short term debt value is unknown

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$946.35 M
APLS annual total expenses is $946.35 million

Annual Operating Expenses

$828.62 M
APLS annual total operating expenses is $828.62 million

Annual Cost Of Goods Sold

$117.72 M
APLS annual cost of goods sold is $117.72 million

Annual SGA

$501.05 M
APLS annual SGA is $501.05 million

Annual D&A

$1.80 M
APLS annual depreciation & amortization is $1.80 million

Annual Interest Expense

$40.39 M
APLS annual interest expense is $40.39 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$87.87 M
APLS annual cash flow from operations is -$87.87 million

Annual CFO 1-Year Change

+85.23%
APLS annual cash flow from operations is up +85.23% year-on-year

Annual CFI

-$403.00 K
APLS annual cash flow from investing activities is -$403.00 thousand

Annual CFI 1-Year Change

+40.21%
APLS annual cash flow from investing activities is up +40.21% year-on-year

Annual CFF

$149.24 M
APLS annual cash flow from financing activities is $149.24 million

Annual CFF 1-Year Change

-62.17%
APLS annual cash flow from financing activities is down -62.17% year-on-year

Free CashFlow

Annual FCF

-$88.27 M
APLS annual free cash flow is -$88.27 million

Annual FCF 1-Year Change

+85.18%
APLS annual free cash flow is up +85.18% year-on-year

CAPEX

Annual CAPEX

$403.00 K
APLS annual capital expenditures is $403.00 thousand

Annual CAPEX 1-Year Change

-47.87%
APLS annual capital expenditures is down -47.87% year-on-year

Institutional Ownership

Similar stocks

SGRY logo
Surgery Partners (SGRY)
AMED logo
Amedisys (AMED)
ALHC logo
Alignment Healthcare (ALHC)
FOLD logo
Amicus Therapeutics (FOLD)
LFST logo
LifeStance Health (LFST)
VKTX logo
Viking Therapeutics (VKTX)
WRBY logo
Warby Parker (WRBY)
MRUS logo
Merus NV (MRUS)
ACAD logo
ACADIA Pharmaceuticals (ACAD)

FAQ

  • What is the ticker symbol for Apellis Pharmaceuticals?
  • Does Apellis Pharmaceuticals pay dividends?
  • What sector is Apellis Pharmaceuticals in?
  • What industry is Apellis Pharmaceuticals in?
  • What country is Apellis Pharmaceuticals based in?
  • When did Apellis Pharmaceuticals go public?
  • Is Apellis Pharmaceuticals in the S&P 500?
  • Is Apellis Pharmaceuticals in the NASDAQ 100?
  • Is Apellis Pharmaceuticals in the Dow Jones?
  • When was Apellis Pharmaceuticals's last earnings report?
  • When does Apellis Pharmaceuticals report earnings?
  • Should I buy Apellis Pharmaceuticals stock now?

What is the ticker symbol for Apellis Pharmaceuticals?

The ticker symbol for Apellis Pharmaceuticals is NASDAQ:APLS

Does Apellis Pharmaceuticals pay dividends?

No, Apellis Pharmaceuticals does not pay dividends

What sector is Apellis Pharmaceuticals in?

Apellis Pharmaceuticals is in the Healthcare sector

What industry is Apellis Pharmaceuticals in?

Apellis Pharmaceuticals is in the Biotechnology industry

What country is Apellis Pharmaceuticals based in?

Apellis Pharmaceuticals is headquartered in United States

When did Apellis Pharmaceuticals go public?

Apellis Pharmaceuticals's initial public offering (IPO) was on November 9, 2017

Is Apellis Pharmaceuticals in the S&P 500?

No, Apellis Pharmaceuticals is not included in the S&P 500 index

Is Apellis Pharmaceuticals in the NASDAQ 100?

No, Apellis Pharmaceuticals is not included in the NASDAQ 100 index

Is Apellis Pharmaceuticals in the Dow Jones?

No, Apellis Pharmaceuticals is not included in the Dow Jones index

When was Apellis Pharmaceuticals's last earnings report?

Apellis Pharmaceuticals's most recent earnings report was on Feb 28, 2025

When does Apellis Pharmaceuticals report earnings?

The date for Apellis Pharmaceuticals's next earnings report has not been announced yet

Should I buy Apellis Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions